单药泰索帝每周方案治疗晚期老年人非小细胞肺癌64例疗效观察

目的:研究和评价单药泰索帝每周方案治疗晚期老年人非小细胞肺癌的临床疗效和不良反应。方法:对1999年11月至2005年2月我院收治的64例年龄在65至84岁的老年晚期非小细胞肺癌患者,应用单药泰素帝每周用药剂量为25mg/m2化疗,连续6周,休息2周,评价疗效和毒性反应。其中25例病人为一线化疗,另39例为二线用药。结果:64例患者共经历448周泰素帝化疗,近期有效24例(37.5%),保持稳定或微效26例(40.6%),中位病情无进展期28周,中位生存期44周。主要毒性反应为乏力,体质下降,发生率20%。骨髓抑制多为1~2度,4度骨髓抑制患者仅1例。结论:单药泰索帝每周方案治疗晚期老年人非小细胞肺癌患者有一定疗效,毒性反应轻微,可使患者病情进展延缓,中位生存期延长。

Weekly docetaxel in the treatment of 64 elderly patients with advanced non -smal cell lung cancer

Objective:To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly patients with advanced non-smal cell lung cancer (NSCLC). Methods: Sixty four patients aged 65~84 with advanced NSCLC received docetaxel 25 mg/m~2 weekly for 6 consecutive weeks, followed by 2 weeks without treatment. The median age of patients was 74 years, 25 patients received weekly docetaxel as first-line treatment, and the other 39 patients as the second-line treatment. Results: A total of 448 doses of weekly docetaxel were administered to 64 patients, 24 patients (37.5%) had objective responses to treatment, and an additional 26 patients (40.6%) had stable disease or minor response. Median time to progression for responding and stable patients was 28 weeks (range, 12 to 76 weeks). Median survival time for the entire group was 44 weeks.Severe neutropenia occurred in only 0.4%, and no other hematologic toxicity was observed. Conclusion: Weekly docetaxel therapy is active and well tolerated by elderly patients with advanced NSCLC. This treatment can be administered with minimal myelosuppression. Weekly docetaxel provides an additional option for treatment in this difficult subgroup of patients with metastatic NSCLC.